ent Naxagolide HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563592

CAS#: 100935-99-7 (S-isomer HCl)

Description: ent Naxagolide is a S-isomer of Naxagolide. ent Naxagolide is a dopamine D2-receptor agonist for the treatment of extrapyramidal disorders, also being an antiparkinson agent.

Chemical Structure

img
ent Naxagolide HCl
CAS# 100935-99-7 (S-isomer HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 563592
Name: ent Naxagolide HCl
CAS#: 100935-99-7 (S-isomer HCl)
Chemical Formula: C15H22ClNO2
Exact Mass: 283.13
Molecular Weight: 283.790
Elemental Analysis: C, 63.48; H, 7.81; Cl, 12.49; N, 4.94; O, 11.28

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 99705-65-4 (HCl)   88058-88-2 (free base)   100935-99-7 (S-isomer HCl)    

Synonym: ent Naxagolide Hydrochloride; ent Naxagolide HCl; MK-458; MK 458; MK458; Naxagolide HCl; Naxagolide Hydrochloride;

IUPAC/Chemical Name: (4aS-trans)-3,4,4a,5,6,10b-Hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol Hydrochloride

InChi Key: NNEACMQMRLNNIL-YYLIZZNMSA-N

InChi Code: InChI=1S/C15H21NO2.ClH/c1-2-7-16-8-9-18-15-13-10-12(17)5-3-11(13)4-6-14(15)16;/h3,5,10,14-15,17H,2,4,6-9H2,1H3;1H/t14-,15-;/m0./s1

SMILES Code: OC1=CC2=C(C=C1)CC[C@@]3([H])[C@@]2([H])OCCN3CCC.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 283.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Moribe K, Pongpeerapat A, Tozuka Y, Yamamoto K. Drug nanoparticle formation from drug/HPMC/SDS ternary ground mixtures. Pharmazie. 2006 Feb;61(2):97-101. PubMed PMID: 16526554.

2: Varshosaz J, Tavakoli N, Eram SA. Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets. Drug Deliv. 2006 Mar-Apr;13(2):113-9. PubMed PMID: 16423799.

3: Krishnaiah YS, Al-Saidan SM, Chandrasekhar DV, Satyanarayana V. Controlled in vivo release of nicorandil from a carvone-based transdermal therapeutic system in human volunteers. Drug Deliv. 2006 Jan-Feb;13(1):69-77. PubMed PMID: 16401596.

4: Rodriguez-Tenreiro C, Alvarez-Lorenzo C, Rodriguez-Perez A, Concheiro A, Torres-Labandeira JJ. New cyclodextrin hydrogels cross-linked with diglycidylethers with a high drug loading and controlled release ability. Pharm Res. 2006 Jan;23(1):121-30. Epub 2006 Dec 7. PubMed PMID: 16320002.

5: McInnes FJ, Thapa P, Baillie AJ, Welling PG, Watson DG, Gibson I, Nolan A, Stevens HN. In vivo evaluation of nicotine lyophilised nasal insert in sheep. Int J Pharm. 2005 Nov 4;304(1-2):72-82. Epub 2005 Sep 23. PubMed PMID: 16183221.

6: Cao QR, Choi YW, Cui JH, Lee BJ. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. J Control Release. 2005 Nov 28;108(2-3):351-61. Epub 2005 Sep 12. PubMed PMID: 16154656.

7: El-Nabarawi MA. Modulation of Tenoxicam release from hydrophilic matrix: modulator membrane versus rate-controlling membrane. Chem Pharm Bull (Tokyo). 2005 Sep;53(9):1083-7. PubMed PMID: 16141572.

8: Mehuys E, Remon JP, Korst A, Van Bortel L, Mols R, Augustijns P, Porter C, Vervaet C. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. J Control Release. 2005 Oct 20;107(3):523-36. PubMed PMID: 16055224.

9: Ruenraroengsak P, Florence AT. The diffusion of latex nanospheres and the effective (microscopic) viscosity of HPMC gels. Int J Pharm. 2005 Jul 25;298(2):361-6. PubMed PMID: 15939561.

10: Wang CY, Ho HO, Lin LH, Lin YK, Sheu MT. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects. Int J Pharm. 2005 Jun 13;297(1-2):89-97. PubMed PMID: 15885936.

11: Qussi B, Suess WG. Investigation of the effect of various shellac coating compositions containing different water-soluble polymers on in vitro drug release. Drug Dev Ind Pharm. 2005 Jan;31(1):99-108. PubMed PMID: 15704861.

12: McConville JT, Ross AC, Florence AJ, Stevens HN. Erosion characteristics of an erodible tablet incorporated in a time-delayed capsule device. Drug Dev Ind Pharm. 2005 Jan;31(1):79-89. PubMed PMID: 15704859.

13: Zhou Y, Li YQ, Su N, Pei XF, Yong L. [Rapid analysis of genetically modified soybean by a duplex PCR-capillary electrophoresis system with laser-induced fluorescence detection]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jan;36(1):119-23. Chinese. PubMed PMID: 15702799.

14: Wu Q, Chen XC, Du SY. [Effect of the sustained release excipients on the release rate of ginsenoside Rg1 and ginsenoside Rb1 in sustained-release tablet of Panax notoginsenosides]. Zhongguo Zhong Yao Za Zhi. 2004 Oct;29(10):944-7. Chinese. PubMed PMID: 15631077.

15: Tang X, Tian X, Ci L. Preparation and evaluation of pH-dependent gradient-release pellets for TCM. Drug Dev Ind Pharm. 2004;30(10):1079-87. PubMed PMID: 15595574.

16: Repka MA, Gutta K, Prodduturi S, Munjal M, Stodghill SP. Characterization of cellulosic hot-melt extruded films containing lidocaine. Eur J Pharm Biopharm. 2005 Jan;59(1):189-96. PubMed PMID: 15567317.

17: Kiortsis S, Kachrimanis K, Broussali T, Malamataris S. Drug release from tableted wet granulations comprising cellulosic (HPMC or HPC) and hydrophobic component. Eur J Pharm Biopharm. 2005 Jan;59(1):73-83. PubMed PMID: 15567304.

18: Odeku OA, Fell JT. Evaluation of khaya gum as a directly compressible matrix system for controlled release. J Pharm Pharmacol. 2004 Nov;56(11):1365-70. PubMed PMID: 15525442.

19: Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC, Takayama K. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm. 2004 Nov;58(3):607-14. PubMed PMID: 15451535.

20: Fu XC, Wang GP, Wang YH, Liang WQ. A predictive model for the release of slightly water-soluble drugs from HPMC matrices. Pharmazie. 2004 Aug;59(8):624-6. PubMed PMID: 15378852.